Anavex Life Sciences Corp (AVXL)

[falconer66a]

With the journal article, everything changes.

Such an publication [of a peer-reviewed journal article] would demonstrate that the MOA of 2-73 is valid.

Exactly. The word will spread. Alzheimer's patients and support groups will focus on blarcamesine; will press to have it approved. No more questions about Anavex or blarcamesine. Clearly, the drug will be the solution to the Alzheimer's problem. Merely a matter of how soon some drug regulatory body approves it somewhere. Owners of Anavex shares will be utterly de-risked.